Bulk Inquiry
COTI-2
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C19H22N6S
- MW: 366.48
Description
COTI-2 is an anti-cancer drug which appears to act both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. Proposed to cause cancer cell death via apoptosis. COTI-2 exhibits potent anti-proliferative activity against a wide variety of human cancer cell lines in vitro (at nanomolar concentrations) and against human tumor xenografts.
More Information
| Parent CAS No. | 1039455-84-9 |
|---|---|
| Chemical Name | N'-(6,7-Dihydroquinolin-8(5H)-ylidene)-4-(pyridin-2-yl)piperazine-1-carbothiohydrazide |
| SMILES | C1N=C(N2CCN(C(N/N=C3/CCCC4C=CC=NC/3=4)=S)CC2)C=CC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C19H22N6S/c26-19(23-22-16-7-3-5-15-6-4-10-21-18(15)16)25-13-11-24(12-14-25)17-8-1-2-9-20-17/h1-2,4,6,8-10H,3,5,7,11-14H2,(H,23,26)/b22-16- |
| InChiKey | UTDAKQMBNSHJJB-JWGURIENSA-N |
| CID | 24857310 |
| Short Description | p53 activator |
References
- KY Salim et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget. 2016 Jul 5;7(27):41363-41379.
- MJ Duffy et al. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017 Sep;83:258-265.
- S Maleki Vareki et al. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS One. 2018 Jan 24;13(1):e0191766.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1871 | Pifithrin-α hydrobromide |
From $104.50 |
| 2016 | NSC 319726 |
From $104.50 |
| 2244 | SCH 529074 |
From $132.00 |
| 2564 | NSC 59984 |
From $104.50 |
| 2879 | CP 31398 |
From $110.00 |
| 3051 | Pifithrin-β |
From $104.50 |
| 3152 | PAWI-2 |
From $132.00 |
| 3277 | NSC194598 |
From $143.00 |
| 4268 | Rezatapopt |
From Inquiry |
| 4278 | Pifithrin-μ |
From $104.50 |
